Updated from 10:30 a.m. EDTWho might be on Eli Lilly's ( LLY) drug company shopping list? Fresh off the $6.5 billion purchase of ImClone Systems, Lilly CEO John Lechleiter says that he's hungry for more drug and biotech deals in the $5 billion to $15 billion range, according to a Wall Street Journal interview. "We're going to look for opportunities to be a bit more diverse pharmaceutical company. We're not going to buy a medical-device company. We're not going to buy a diagnostic company," he told the Journal. Lechleiter didn't reveal which companies he's looking at, but let's take some educated guesses.